References
1. American Cancer Society. Breast Cancer Facts & Figures 2011-2012.
2. Miller KD, Dul CL. Breast cancer: the role of angiogenesis and antiangiogenic therapy. Hematol Oncol Clin N Am 2004;18:1071-1086.
3. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357:2666-2676
4. Gray R, Bhattacharya S, Bowden C, Miller K, Comis RL. Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel in women with metastatic breast cancer. J Clin Oncol 2009;27:4966-4972.
5. Miles D, Chan A, Romieu L, et al. Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent of metastatic breast cancer: AVADO. J Clin Oncol, Proc ASCO 2008;26:LBA1011.
6. Robert NJ, Dieras V, Brufsky GA, et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of HER-2-negative locally recurrent or metastatic breast cancer. J Clin Oncol 2009;27(15s):abstr 1005.
7. Miller KD, Chap LI, Holmes FA, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005;23:792-799.
8. Brufsky A, Bondarenko IN, Smirnov V, et al. RIBBON-2: A randomized, double-blind, placebo controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of HER-2-negative metastatic breast cancer. SABCS; December 9-13, 2009:abstr. 42.
9. Baselga J, Costa F, Geulio MS, et al. SOLTI-0701: A multinational double-blind, randomized phase 2b study evaluating the efficacy and safety of sorafenib compared to placebo when administered in combination with capecitabine in patients with locally advanced or metastatic breast cancer. SABCS; December 9-13, 2009:abstr. 45.
10. Gradishar WJ, Kaklamani V, Prasad Sahoo T, et al. A double-blind, placebo-controlled phase 2b study evaluating the efficacy and safety of sorafenib in combination with paclitaxel as a first-line therapy in patients with locally recurrent or metastatic breast cancer. SABCS; December 9-13, 2009:abstr. 44.
11. Pegram M, Chan D, Dichmann RA, et al. Phase II combined biological therapy targeting the HER2 proto-oncogene and the vascular endothelial growth factor using trastuzumab and bevacizumab as first-line treatment of HER-2-amplified breast cancer. SABCS 2006:abstr. 3039.
12. Rydén L, Jirström K, Bendahl PO, et al. Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer. J Clin Oncol 2005;23:4695-4704
13. Traina TA, Rugo HS, Caravelli JF, et al. Feasibility trial of letrozole in combination with bevazcizumab in patients with metastatic breast cancer. J Clin Oncol. Published ahead of print, October 19, 2009.
14. Isaacs C, Wilkinson M, Liu MC, et al. Phase II study of sorafenib with anastrozole to overcome resistance to aromatase inhibitors in patients with hormone receptor positive (ER/PR+) AI resistant metastatic breast cancer. SABCS, December 9-13, 2009:abstr. 3090.
15. Colleoni M, Orlando L, Sanna G, et al. Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects. Ann Oncol 2006;17:232-238.
16. Dellepasqua S, Bertonloni F, Bagnardi V, et al. Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. J Clin Oncol 2008;26:4899-4905.
17. Targeting Tumor Angiogenesis; Antiangiogenic therapy: tolerability and management of side effects. The Angiogenesis Foundation, Summer 2009.
18. Robert C, Soria JC, Spatz A, et al. Cutaneous side effects of kinase inhibitors and blocking antibodies. Lancet Oncol 2005;6:491-500.
19. Pfizer Inc. Sutent Prescribing Information. Available at:
https://www.pfizeroncology.com/produ...indication.jsp. Accessed January 23, 2009.
20. Rini BI, et al. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2007;99:81-83.
- See more at:
http://www.scienceofcancers.org/brea....U6ow2ZJj.dpuf